Vincent A. Memoli

Dartmouth–Hitchcock Medical Center

Papers

1

Total Citations

67

H-Index

1

About

Vincent A. Memoli is a prominent investigator in cancer biology, with a focused expertise in lung cancer pathogenesis and targeted therapeutics. His research centers on the molecular mechanisms driving tumor growth, particularly the deregulation of cell cycle machinery. Memoli’s major contribution lies in elucidating the consequences of targeting the cyclin E-Cdk-2 complex, a critical regulator often disrupted in lung carcinogenesis. In his highly cited 2009 study (67 citations), he demonstrated that inhibiting this complex does not merely arrest cell division but triggers a novel form of cell death termed “anaphase catastrophe,” thereby repressing lung cancer growth. This work provided a mechanistic rationale for developing therapies that exploit this vulnerability, moving beyond traditional approaches. His findings have informed chemopreventive strategies and advanced the understanding of how cell cycle inhibitors can be leveraged for clinical benefit. Through his research, Memoli has established a framework for targeting cyclin-dependent kinases in lung cancer, offering a promising avenue for more effective treatments.

Research Focus

Key Achievements

1
H-Index
1
Papers
67
Total Citations
67
Avg Citations/Paper
🏆 Most Cited Paper
Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe
67 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Dartmouth–Hitchcock Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago